Results 311 to 320 of about 101,548 (353)

Glucagon-like peptide-1 receptor agonists and the eye

Current Opinion in Ophthalmology
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown.
David L, Zhang, Avni P, Finn
openaire   +2 more sources

Glucagon-like peptide-1 receptor agonists

2016
Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
openaire   +1 more source

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis

Diabetes, obesity and metabolism
Diabetes is an independent risk factor for muscle mass loss, with possible mechanisms including impaired insulin signalling and chronic inflammation.
R. Jiao, Chu Lin, X. Cai, Jingxuan Wang, Yuan Wang, Fang Lv, Wenjia Yang, Linong Ji   +7 more
semanticscholar   +1 more source

[The glucagon-like peptide-1 receptor-agonist semaglutide].

Ugeskrift for laeger, 2020
Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes.
Amalie Dyhrberg, Boje, Christian Rimer, Juhl, Signe Sørensen, Torekov, Sten, Madsbad   +3 more
openaire   +1 more source

Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists

Annals of Pharmacotherapy, 2012
Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted in adults.
Kathryn M, Hurren, Nicole R, Pinelli
openaire   +2 more sources

Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation.

Cell Metabolism, 2023
Chi Kin Wong, Brent A. McLean, L. Baggio, J. Koehler, Rola Hammoud, N. Rittig, Julian M Yabut, Randy J. Seeley, Theodore J Brown, D. J. Drucker   +9 more
semanticscholar   +1 more source

Periconceptional Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation

JAMA Cardiology
This Viewpoint describes the need for more studies on the best timing for dicontinuation of glucagon-like peptide-1 receptor agonists before pregnancy.
Sadiya S, Khan, William A, Grobman, Dhruv S, Kazi   +2 more
openaire   +2 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly